The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
• The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study
• Age range of 18-75 years old upon enrollment, both male and female are eligible
• Stage III NSCLC confirmed by histology or cytology (according to the International Union Against Cancer and the Joint American Committee on Cancer 8th edition TNM staging of lung cancer)
• It was clarified that surgical resection is not possible After MDT discussion,
• The main driver genes have no sensitive mutations (including EGFR, ALK, ROS1, MET, HER2, etc.)
• No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC
• According to RECIST v1.1, there is at least one measurable lesion, and according to RECIST v1.1, this lesion is suitable for repeated and accurate measurements
• There is sufficient organ function reserve to meet the needs of clinical research